Baxter International (NYSE:BAX) Posts Quarterly Earnings Results, Beats Estimates By $0.06 EPS

Baxter International (NYSE:BAX) released its quarterly earnings data on Thursday. The medical instruments supplier reported $0.58 EPS for the quarter, topping the consensus estimate of $0.52 by $0.06, FiscalAI reports. Baxter International had a positive return on equity of 16.48% and a negative net margin of 6.23%. The firm had revenue of $2.98 billion for the quarter, compared to the consensus estimate of $2.91 billion. During the same quarter in the previous year, the business earned $0.69 earnings per share. The company’s quarterly revenue was up 5.0% on a year-over-year basis.

Here are the key takeaways from Baxter International’s conference call:

• Third-quarter results exceeded expectations: Sales rose 5% organically to approximately $3 billion, with broad-based growth led by Advanced Surgery, drug compounding, and infusion systems. Baxter raised its 2026 organic sales growth outlook to 3%-4% and lifted the low end of adjusted EPS guidance to $2.05-$2.15.
• Cash flow and deleveraging improved: Third-quarter free cash flow was $448 million, bringing year-to-date free cash flow to $705 million. Baxter also completed a $600 million tender offer that retired $854 million of debt and remains confident in reaching approximately 3x net leverage by year-end.
• Operational improvements continued across the portfolio, including better on-time shipments, improved quality metrics, cost savings, and more than 700 Baxter GPS continuous-improvement initiatives completed year to date. Advanced Surgery grew 12%, while HST margins expanded 140 basis points.
• Quality and portfolio actions create near-term pressure: Baxter will discontinue cephalosporin production at its Round Lake facility following supply and FDA warning-letter issues; the products are expected to contribute approximately $50 million in 2026 sales and $30 million in operating income. Management also flagged 2027 headwinds from product exits, the loss of tariff-refund benefits, inflation, tariffs, and the end of Vantive-related TSA services.

Baxter International Price Performance

Shares of BAX traded down $0.55 during trading hours on Friday, reaching $22.95. 11,809,880 shares of the stock traded hands, compared to its average volume of 6,506,524. The company has a market cap of $11.87 billion, a P/E ratio of -16.28, a price-to-earnings-growth ratio of 3.54 and a beta of 0.65. The company has a current ratio of 1.95, a quick ratio of 1.32 and a debt-to-equity ratio of 1.39. The company’s 50-day moving average price is $24.59 and its two-hundred day moving average price is $21.37. Baxter International has a 52-week low of $15.73 and a 52-week high of $30.00.

Baxter International Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Monday, January 4th. Investors of record on Friday, November 27th will be paid a dividend of $0.01 per share. The ex-dividend date is Friday, November 27th. This represents a $0.04 dividend on an annualized basis and a dividend yield of 0.2%. Baxter International’s payout ratio is -2.84%.

More Baxter International News

Here are the key news stories impacting Baxter International this week:

• Positive Sentiment: Baxter reported third-quarter adjusted earnings of $0.58 per share, exceeding the $0.52 analyst consensus, while revenue increased 5% year over year to $2.98 billion and topped expectations of $2.91 billion. Growth was described as broad-based across the company’s segments. Baxter Q3 Earnings Beat on Broad-Based Growth, 2026 Outlook Raised
• Positive Sentiment: Management raised its full-year 2026 earnings outlook, signaling confidence in operating performance despite ongoing pressure on profitability. However, quarterly EPS remained below the $0.69 reported a year earlier. Baxter Raises 2026 Earnings Guidance
• Positive Sentiment: Wells Fargo raised its price target for BAX to $25 from $23, implying potential upside from recent trading levels. The firm maintained an “equal weight” rating, suggesting a constructive but cautious view. Wells Fargo Baxter Analyst Ratings
• Neutral Sentiment: Baxter declared a quarterly dividend of $0.01 per share, or $0.04 annualized. The approximately 0.2% yield provides minimal income support but maintains a cash-return program. Baxter Raises Guidance and Declares Dividend
• Negative Sentiment: The FDA issued Baxter a warning letter citing CGMP violations. The regulatory action could increase remediation costs, create operational disruptions, and raise concerns about compliance and product quality. Baxter Received FDA Warning Letter

Wall Street Analyst Weigh In

A number of research firms recently commented on BAX. Weiss Ratings upgraded shares of Baxter International from a “sell (d-)” rating to a “sell (d)” rating in a report on Friday. UBS Group raised their price objective on Baxter International from $19.00 to $25.00 and gave the company a “hold” rating in a research report on Tuesday, July 28th. Barclays assumed coverage on Baxter International in a research report on Wednesday, October 7th. They issued an “underweight” rating and a $20.00 price target on the stock. TD Cowen increased their price objective on shares of Baxter International from $20.00 to $24.00 and gave the company a “hold” rating in a research report on Monday, July 27th. Finally, Zacks Research upgraded Baxter International from a “strong sell” rating to a “hold” rating in a research note on Tuesday, August 11th. One investment analyst has rated the stock with a Buy rating, ten have assigned a Hold rating and three have issued a Sell rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Reduce” and an average target price of $23.00.

Baxter International Company Profile

Baxter International Inc is a global medical products and healthcare technology company headquartered in Deerfield, Illinois. The company develops, manufactures and distributes products used in hospitals, clinics, ambulatory care centers and other healthcare settings.

Baxter’s portfolio has included intravenous therapies and administration systems, infusion pumps, connected-care technologies, surgical products, patient monitoring equipment and products used in medication preparation and delivery.